Tempus AI Buys Personalis for $1.5B in MRD Cancer Push

Tempus just bought its way deeper into cancer monitoring — a one-and-a-half-billion-dollar bet on catching a tumor coming back before a scan ever could.

Samsung writes an all-cash check for a Swiss peptide maker, Legend's stock drops on a record quarter, and a CRISPR pioneer tests whether the IPO window is really open. Busy Monday. Let's get into it.

Welcome to The Pharma Closeout for Monday, July 20th. I'm Alex Mercer.

And I'm Maya Patel.

Tempus AI agreed this morning to buy Personalis — sixteen twenty-five a share, roughly one-and-a-half billion enterprise value, all stock, net of the stake Tempus already owns. Filing hit EDGAR before the open. And here's what's actually happening: Tempus isn't buying a lab. It's buying vertical control of molecular residual disease before the reimbursement curve bends.

OK, but here's my issue with that framing. The company is calling MRD a twenty-billion-dollar opportunity — that's a Tempus number, straight from the release. And the honest read is that MRD reimbursement is still early. Coverage is patchy outside colorectal, and the interventional question — does acting on an MRD signal actually change overall survival — is largely unsettled. So what is Tempus really paying for?

That's fair. But that's exactly why you buy now instead of in three years. These two have been partnered since 2023 — Tempus already commercializes the NeXT Personal test. If you believe reimbursement inflects, you want the asset before the price reflects it, not after.

Then the synthesis isn't "Tempus bought a market" — it's "Tempus bought timing." They're paying a modest premium for an ultrasensitive, tumor-informed platform on a bet that the clinical-utility evidence and the coverage decisions arrive together. If either one lags, this is dilution without a return. And that's the tension going into earnings.

And dilution is the live wire. It's all stock, and Tempus reports July 30th. This is the fourth-largest holding in Cathie Wood's ARK Innovation fund — about five and a half percent of the portfolio. Existing holders get asked to absorb more paper right before the numbers land. Let's bring in Marcus Webb on the structure.

The competitive read: if you're running commercial strategy in oncology diagnostics, the MRD land-grab just accelerated. Tempus locked in its monitoring rail — and anyone still shopping for one is now negotiating against a fully integrated competitor.

And the thread I'm watching is that July 30th call. If Tempus can't frame the dilution against a credible adoption ramp, the market punishes the paper long before the platform ever proves out.

Shifting to the deal side — and this next one, we've been tracking since May. Samsung Biologics finally pulled the trigger on PolyPeptide. One-point-eight billion, all cash, forty-four Swiss francs thirty-one a share, about a six percent premium, board unanimously behind it. Samsung just bought a seat at the GLP-1 supply table.

The strategic logic is cleaner than that premium suggests. Samsung's been an antibody-and-ADC shop, and peptides are the fastest-growing corner of contract manufacturing right now — almost entirely on obesity-drug demand. Eastern Herald's calling it the largest biotech deal in South Korean history. Samsung isn't buying a molecule. It's buying capacity in the one modality it couldn't credibly offer. That's a CDMO defending against irrelevance.

Right — and speaking of stories we flagged last week, Legend Biotech. Carvykti posted about six hundred fifty-seven million in net trade sales for the second quarter — up ten percent sequentially, a record. And the stock fell around ten percent, on a wider-than-expected loss.

Which is the whole story of cell therapy in a single session. Demand isn't the question anymore — cost of goods is. Investors punished the margin, not the molecule. Simply Wall St pegs fair value near fifty-seven dollars and calls it undervalued — but that thesis only holds if Legend shows a path to profitability, not just more vials shipped.

Let me run the quick hits. That Lilly–AtaiBeckley psychedelics deal from Friday — Endpoints now reports both J&J and AbbVie kicked the tires before Lilly's two-point-eight-billion move. So that was a bidding war, not a reach. GSK, meanwhile, quietly shelved a chronic cough drug it acquired in a two-billion-dollar deal — the asset's dead. And Bristol Myers says it'll build pharma's "most powerful" AI supercomputer with Nvidia — no dollar figure, and at least the third company to claim that same crown this year. That one's Pharma Theatre until there's a molecule attached.

The GSK line is the one I'd sit with. Two billion in, and they walked. That's the cost of platform-era optionality — you pay upfront and sometimes the asset just doesn't read out. It's the unglamorous other side of the deal machine everyone's celebrating right now.

And on the financing side — the IPO window we've been circling all month. Scribe Therapeutics, the CRISPR shop founded by Jennifer Doudna, set terms today: roughly a ninety-six-million-dollar raise, up to a hundred and seven at the top. UK biotech VC funding also just hit a record high per Endpoints. Money's clearly moving.

Scribe is the real tell. Early-stage, pre-Phase 3, Doudna's name on the S-1. If that prices clean, the window isn't cracked — it's open. And that's the read-through for every private biotech sitting on a delayed raise, watching to see if someone goes first.

On the regulatory front — and we've been tracking this one too — Takeda landed India's first dengue vaccine approval. Fierce's tracker had it this morning. India's one of the highest-burden dengue markets on the planet, so the volume opportunity is enormous. But this is a public-health-price market. The story is access and manufacturing scale, not margin.

And it's a beachhead. Takeda's been building this dengue franchise globally, and India's the volume anchor that makes the surrounding program economics work.

There's a quieter development worth the airtime, though. Novartis's Fabhalta picked up full FDA approval in IgA nephropathy last week. The angle I'm watching isn't the approval — it's the label breadth. A broad IgAN indication reshapes the competitive map against the other complement players faster than anyone modeled.

And one that flew under the radar entirely — the FDA paused its policy of publishing drug-rejection letters in real time while it formalizes the approach. For anyone running competitive intelligence, that matters. The window that briefly let you read a rival's rejection rationale just narrowed.

And that's the implication. Less visibility into why a competitor got rejected means slower reads on where the agency's drawing its lines. The edge shifts back to whoever has the best regulatory relationships — not the best FOIA habits.

Looking ahead — Tempus reports July 30th, and that call is now a referendum on whether the Personalis dilution buys a story the market believes.

I'm watching the IPO tape. Scribe prices this week, and there's a queue right behind it — Latigo, BlossomHill, Generate Biomedicines targeting north of two billion in valuation. One clean pricing tells every private biotech the exit is back.

And keep half an eye on Pfizer — downgraded to Hold on delayed catalysts and management churn. Not a catalyst itself, but a sentiment marker for every large-cap carrying patent-cliff weight. Oruka Therapeutics also dropped after Fairmount unloaded a three-hundred-million-dollar stake — worth noting as the small-cap tape stays jumpy.

The through-line for the week: capital's moving again — into diagnostics, into peptides, into early-stage CRISPR. The open question is whether the reimbursement and the readouts show up before the checks clear.

And that's your Pharma Closeout for Monday, July 20th — Tempus reaching for Personalis and the MRD market, Samsung buying its way into GLP-1 peptides, Legend's Carvykti record that the market hated, and Scribe testing whether the IPO window is real. If you want to stay across this space, subscribe wherever you listen — we're back tomorrow.

Fast start to the week — and it only accelerates from here. We'll be back tomorrow with the first read on where that IPO window heads next. See you then!